Matteo Sepulcri

Radiation Oncologist, main focus on prostate and lung. Basketball lover. #radonc

[Roberto Ferrara @RobertoFerrara_]

Does nodal irradiation explain the negative results of concurrent Chemo-ICI-RT observed in Pacific-2 and Checkmate 73L? Better a 'perioperative like' strategy Chemo-ICI ->ChemoRT->ICI?
Novel scenarios for unresectable stage III NSCLC discussed by @AntonioNuccio01 and @mat_sepu

[Alessandro Di Federico @DiFedericoMD]

Fully published @JTOonline our individual patient data meta-analysis on EFS in pts w/ resectable NSCLC treated w/ neoadj Chemo-IO.
An effort led by @dmarinelli93 @AntonioNuccio01 @filippog92 on behalf of a young Italian multidisciplinary oncology group
https://t.co/SOGodeO8UV
1/4

[Stephen V Liu, MD @StephenVLiu]

Individual patient data meta-analysis @JTOonline of neoadjuvant or perioperative trials in resectable NSCLC shows pCR or MPR with neoadjuvant chemo-immunotherapy associated with improved EFS, similar with or without adjuvant immunotherapy component.

https://t.co/gYKaW4K365

[Over @OverEventi]

Sala gremita a Castelfranco Veneto durante i lavori del 2° giorno di 'Advanced Uro-Oncology'.
Un evento dedicato ad oncologi, urologi e radioterapisti con Resp. Scientifici Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. @therealmarcodoc @PorrecaAngelo @mat_sepu

[Over @OverEventi]

Grande successo per la 2° edizione del congresso ‘Advanced Uro-Oncology’ a Castelfranco Veneto.
Responsabili Scientifici: Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. @therealmarcodoc @PorrecaAngelo @mat_sepu
#Oncologia #Urologia #Radioterapia

[Over @OverEventi]

A partire da domani 18 e 19 aprile a Castelfranco Veneto (TV)
Advanced Uro-Oncology Days

Responsabili Scientifici Dott.ri Marco Maruzzo, Angelo Porreca, Matteo Sepulcri. @therealmarcodoc @mat_sepu

Programma ed iscrizioni: https://t.co/2EZTpM5RV9

[Pierre Blanchard, MD @PBlanchardMD]

LUNG-ART trial out in @TheLancetOncol: https://t.co/dw5texoMD2

Postoperative #radiotherapy in IIIA pN2 NSCLC pts
- no increase in DFS (HR 0.86, p=0.18) or OS
- increase in late G3/4 cardiopulm tox

Negative results but huge work by Dr Cécile Le Péchoux from @GustaveRoussy #lcsm

[Matteo Sepulcri @mat_sepu]

Metabolic features can predict response to radical RT for prostate cancer! #PCSM

Happy to share our latest work with many thanks to all colleagues and friends @lauraevangelis9 @MarcoFusella

https://t.co/NGUnYQKRKg

[Matteo Sepulcri @mat_sepu]

@AiroLung

[Henning Willers, MD, FASTRO @HenningWillers]

PORT-C: No improved DFS or OS with 50 Gy PORT for stage IIIA(N2) #lungcancer. Positive impact on LR.
https://t.co/L5yJ4ltH4Z
Well tolerated but unclear if cardiac events were monitored (subcarinal included).
In contrast to LungART, almost 90% treated with IMRT.
#OncoAlert #LCSM

[Paul Sargos @PaulSargos]

So proud to present our Guidelines for Radiotherapy of Bladder Cancer
➡️ GETUG-AFU Recommendations for planning and delivery of radical radiotherapy for ... https://t.co/KTlKGfcjgE

[Matthias Guckenberger @Mat_Guc]

Updated meta-analysis of PORT for completely resected Masaoka stage II/III Thymoma
☑️ n=4746 pts
⬆️ OS with HR=0.68
⬆️ Similar beneficial effect in stage II and III
#radonc
https://t.co/DeBJbnRDNE

[Matthias Guckenberger @Mat_Guc]

Prospective single arm phase II trial of SBRT for oligometastatic NSCLC
➡️ SBRT was delivered after 2-4 mo systemic Tx
➡️ About 40% were treated with TKI
➡️ Sig. improved PFS for pts with complete metabolic response (median 54 mo)
➡️ No G4 tox
#radonc
https://t.co/1sOJLe94ef

[Corinne Faivre-Finn @finn_corinne]

Delighted to present updated data from the PACIFIC trial in unresectable Stage III NSCLC @myESMO
Durable benefit with durvalumab @4 years
- almost 50% of patients alive
- MS reached for the first time and is an unprecedented 47.5 months
=major benefit for patients @MCRCnews

[Raj Singh, MD @Raj_Singh_MD]

Our recently completed meta-analysis comparing conventional RT to SRS for management of spinal metastases just published in the Green Journal! @EricLehrer @NicholasZaorsky @DanTrifMD https://t.co/iJDYn9npHU

[Sean Collins Prostate SBRT @ USF Health @SbrtSean]

Red Journal: Article in Press!

Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer

Deek et al.

https://t.co/pkedmvm21e.

[European Urology @EUplatinum]

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel mCRPC Identifies an Excess of Long-term Survivors
#VisualAbstract
@AlbertoBossial @HouedeNadine @neerajaiims
https://t.co/lqq2QEhryl

[radoncreview_org @radoncreview]

ESTRO-ACROP guidelines for Target Volume Definition in #SCLC:
-Consider clusters of smaller LNs with SAD < 1 cm.
-Consider ipsi SCV if level 2 or 3a involved.
-CTV = GTV + 5 mm, particularly in CC direction for nodes.
-No adaptive nodal cone-down. #radonc
https://t.co/j6vZj5N8Bh

[Corinne Faivre-Finn @finn_corinne]

Our paper on the effect of radiotherapy-related lymphopenia on overall survival in patients with lung cancer utilizing image-based data mining is now published online in @JTOonline
https://t.co/6ltBVHIQjB
@AzadehAbravan @RT_physics @MCRCnews

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Meta-analysis of radiotherapy for prostate cancer: 8 weeks (conventional fractionation) vs 5 weeks (hypofractionation) vs ~1 week (ultra-hypofractionation) of treatment

@EricLehrer @AmarUKishan @jamesbyu @DanTrifMD @TimShowalter1 @OncologyAdvance
#pcsm #RadOnc

[Matteo Sepulcri @mat_sepu]

@AiroLung #radonc

[Stephen V Liu, MD @StephenVLiu]

#ASCO20 A lot to think about with the data from the #SINDAS trial: a randomized phase 3 trial of early local radiation therapy for patients with metastatic #EGFR mutant #NSCLC presented by Dr. Xiao-Shan Wang. #OncoAlert #LCSM